(function() {
try {
var cs = document.currentScript,
p = (document.cookie.split(‘gnt_i=’)[1] || ”) + ‘;’,
l = p.substring(p.indexOf(‘~’) – 2, p.indexOf(‘;’));
if (!l) {
var n = window.performance && performance.getEntriesByType(‘navigation’) || [],
st = n[0].serverTiming || ”;
if (st.length) {
for (const t of st) {
if (t.name === ‘gnt_i’) {
l = t.description.split(‘*’)[2];
break;
}
}
}
}
if (l) {
var g = decodeURIComponent(l).split(‘~’);
comply({
country: g[0],
city: g[2],
zipcode: g[3],
state: g[1]
});
} else {
comply();
}
} catch(e) {
comply();
}
function comply(loc) {
if(window.ga_privacy) return;
loc = loc || {};
var host = window.location.hostname || ”,
eu = host.split(‘.’)[0] === ‘eu’,
cco = hp(‘gnt-t-gc’),
sco = hp(‘gnt-t-gs’),
cc = cco || loc.country || (eu ? ‘ES’ : ‘US’),
sc = sco || loc.state || (cc === ‘US’ ? ‘CA’ : ”),
t = true,
gdprLoc = {‘AT’: t, ‘BE’: t, ‘BG’: t, ‘HR’: t, ‘CY’: t, ‘CZ’: t, ‘DK’: t, ‘EE’: t, ‘EL’: t, ‘EU’: t, ‘FI’: t, ‘FR’: t, ‘DE’: t, ‘GR’: t, ‘HU’: t, ‘IE’: t, ‘IT’: t, ‘LV’: t, ‘LT’: t, ‘LU’: t, ‘MT’: t, ‘NL’: t, ‘PL’: t, ‘PT’: t, ‘RO’: t, ‘SK’: t, ‘SI’: t, ‘ES’: t, ‘SE’: t, ‘NO’: t, ‘LI’: t, ‘IS’: t, ‘AD’: t, ‘AI’: t, ‘AQ’: t, ‘AW’: t, ‘AX’: t, ‘BL’: t, ‘BM’: t, ‘BQ’: t, ‘CH’: t, ‘CW’: t, ‘DG’: t, ‘EA’: t, ‘FK’: t, ‘GB’: t, ‘GF’: t, ‘GG’: t, ‘GI’: t, ‘GL’: t, ‘GP’: t, ‘GS’: t, ‘IC’: t, ‘IO’: t, ‘JE’: t, ‘KY’: t, ‘MC’: t, ‘ME’: t, ‘MS’: t, ‘MF’: t, ‘MQ’: t, ‘NC’: t, ‘PF’: t, ‘PM’: t, ‘PN’: t, ‘RE’: t, ‘SH’: t, ‘SM’: t, ‘SX’: t, ‘TC’: t, ‘TF’: t, ‘UK’: t, ‘VA’: t, ‘VG’: t, ‘WF’: t, ‘YT’: t},
gdpr = !!(eu || gdprLoc[cc]),
gppLoc = {‘CA’: ‘usca’, ‘NV’: ‘usca’, ‘UT’: ‘usnat’, ‘CO’: ‘usco’, ‘CT’: ‘usct’, ‘VA’: ‘usva’, ‘FL’: ‘usnat’, ‘MD’: ‘usnat’,’MN’: ‘usnat’, ‘MT’: ‘usnat’, ‘OR’: ‘usnat’, ‘TN’: ‘usnat’, ‘TX’: ‘usnat’, ‘DE’: ‘usnat’, ‘IA’: ‘usnat’, ‘NE’: ‘usnat’, ‘NH’: ‘usnat’, ‘NJ’: ‘usnat’, ‘IN’: ‘usnat’, ‘KY’: ‘usnat’, ‘RI’: ‘usnat’},
gpp = !gdpr && gppLoc[sc];
if (gdpr && !window.__tcfapi) {
“use strict”;function _typeof(t){return(_typeof=”function”==typeof Symbol&&”symbol”==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&”function”==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?”symbol”:typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement(“iframe”);r.style.cssText=”display:none”,r.name=”__tcfapiLocator”,e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r3&&2===parseInt(n[1],10)&&”boolean”==typeof n[3]&&(e=n[3],”function”==typeof n[2]&&n[2](“set”,!0)):”ping”===n[0]?”function”==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:”stub”}):o.push(n)},n.addEventListener(“message”,(function(t){var e=”string”==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n=”object”===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,”*”)}),n.parameter)}),!1))};”undefined”!=typeof module?module.exports=t:t()}();
}
if (gpp && !window.__gpp) {
window.__gpp_addFrame=function(e){if(!window.frames[e])if(document.body){var p=document.createElement(“iframe”);p.style.cssText=”display:none”,p.name=e,document.body.appendChild(p)}else window.setTimeout(window.__gppaddFrame,10,e)},window.__gpp_stub=function(){var e=arguments;if(__gpp.queue=__gpp.queue||[],!e.length)return __gpp.queue;var p,n=e[0],t=1function OptanonWrapper() { }Skip to main content
![]()
(function() {
let vdContainer, vdShow, vdHide,
flagCaption = false,
vdToggle = document.getElementById(‘videoDetailsToggle’),
section = ga_data.route.sectionName || ga_data.route.ssts.split(‘/’)[0],
subsection = ga_data.route.ssts.split(‘/’)[1];
vdToggle.addEventListener(‘click’, ()=> {
// query dom only after user click
if (!vdContainer) {
vdContainer = document.getElementById(‘videoDetailsContainer’);
vdShow = document.getElementById(‘vdt_show’),
vdHide = document.getElementById(‘vdt_hide’);
}
vdContainer.hidden = !(vdContainer.hidden);
// show/hide elements
if (vdContainer.hidden) {
vdShow.hidden = false;
vdHide.hidden = true;
} else {
if (!flagCaption) {
flagCaption = true;
fireCaptionAnalytics()
}
vdShow.hidden = true;
vdHide.hidden = false;
}
});
function fireCaptionAnalytics () {
let analytics = document.getElementById(“pageAnalytics”);
try {
if (analytics) {
analytics.fireEvent(`${ga_data.route.basePageType}|${section}|${subsection}|streamline|expandCaption`);
} else {
if (window.newrelic) window.newrelic.noticeError(‘page analytics tag not found’);
}
} catch (e) {
if (window.newrelic) window.newrelic.noticeError(e);
}
}
}());
America is finally catching up on its sunscreen options.
The Food and Drug Administration (FDA) announced that it approved bemotrizinol, an ingredient already popular in other countries, for use in American sunscreens on Tuesday, June 9, marking the first time a new ingredient has been introduced since the 1990s.
“Bemotrizinol has been used safely in Europe for decades, and FDA's action will increase competition and consumer confidence in sunscreen products,” Health and Human Services Secretary Robert F. Kennedy Jr. said in a news release.
The agency first announced plans to review bemotrizinol for use in sunblock in December, with then-FDA Commissioner Marty Makary saying the FDA has “historically moved too slowly in this area, leaving Americans with fewer options than consumers abroad.”Â
The process of approving the ingredient was expedited under what’s known as the CARES Act, signed into law in 2020 by then-President Joe Biden. The legislation amended a cumbersome, multi-step process for over-the-counter drugs in an effort to create a more efficient system.
“The FDA announcement follows longstanding and ongoing advocacy by the American Academy of Dermatology Association,” Dr. Murad Alam, President of the American Academy of Dermatology, told USA TODAY in a statement. “The AADA believes this approval marks an important public health step by expanding access to safe and effective sunscreens for consumers in the United States and helping save the lives of Americans from skin cancer, one of the most preventable cancers.”
What is Bemotrizinol?
Bemotrizinol, or BEMT, is a chemical compound that absorbs both UVB and UVA rays. If those sound familiar, it’s because you’ve probably already seen them on every bottle of sunscreen you’ve ever purchased. The sun emits ultraviolet (UV) radiation, the thing sunscreens are designed to protect against.
Names like UVB and UVA distinguish between the different kinds of rays that make up the radiation, according to the University of Texas MD Anderson Cancer Center. As far as our skin, the difference between the two isn’t huge. Tanning and burns happen faster with UVA than UVB. And UVB can be filtered by barriers like windows and clouds.
About 95% of UV that reaches the ground is UVA, with UVB making up the additional 5%, according to the Anderson Cancer Center.
Sunblock protects against both in two different ways: putting a physical barrier between your skin and the sun with minerals or by using a chemical that absorbs rays before they can reach you. BEMT is one of the latter.
Why is BEMT good for use in sunscreen? Is it better for children?
BEMT offers a lot of what we look for in a sunscreen. It’s broad-spectrum, meaning it protects against both UVA and UVB, and offers a higher Sun Protection Factor (SPF) in smaller amounts than other popular ingredients, according to the FDA.
BEMT is also more photostable than other commonly used sunscreen ingredients, meaning it breaks down in the sun more slowly, Dr. Nisha Varadarajan, dermatologist at the Memorial Sloan Kettering Cancer Center, told USA TODAY. It’s also oil-soluble, which makes it ideal for incorporating into creams.
It has low levels of absorption through the skin into the body, remaining on the skin surface rather than penetrating it. As a result, less of it ends up in your system. This is in contrast to some other chemical filters used in U.S. sunscreen, which a 2019 FDA review found often ended up in the body at plasma levels above the accepted FDA threshold.
It is also unlikely to cause skin irritation, which the FDA says makes it suitable for safe use in children as young as 6 months of age. In fact, bemotrizinol is a first-of-its-kind in being recommended for very young children.
“The current sunscreen recommendations for infants 6 months and older are mineral sunscreens containing zinc oxide and titanium dioxide, as these are less irritating on sensitive skin compared to chemical filters,” said Varadarajan. “Bemotrizinol would be the first chemical UV filter recommended to be used on infants due to minimal skin irritation.”
When will BEMT come to sunscreen in the US? Can you buy it now?
Beginning Aug. 9, 2026, sunscreen manufacturers can include bemotrizinol as an active ingredient in sunscreens.
Bemotrizinol sunscreen will first be sold in the United States under the brand name Parsol Shield by the Dutch manufacturer DSM Nutritional Products and is expected to be available later this year. After an 18-month exclusive period, other manufacturers will be allowed to follow suit with their own products.
Share your feedback to help improve our site!





![[Podcasts] Defense of the day – Yael Mellul, columnist: “Who am I to judge this legitimate choice which is deeply intimate? They do not want to undergo this social pressure on parenthood and demographic rearmament” – 10/06](https://images.bfmtv.com/yJd-gCNemZ6_42s2U2eCQlRFhTE=/0x0:12000x6280/1200x0/images/image_composition_EN-202606100559.jpg)